J P M O R G A N Asia Pacific Equity Research 23 July 2026 Chugai Pharmaceutical (4519) Overseas results: Roche, Galderma 2Q FY2026 Roche and Galderma (both covered by Richard Vosser) announced 2Q (April- June) FY2026 results at 14:00 JST on July 23. Conference calls will be held at 21:00 by Roche and at 20:00 by Galderma. Chugai Pharmaceutical is due to announce its 2Q FY2026 results at 16:00 on July 24, followed by a conference call at 17:00. Among Roche's products, Hemlibra and Actemra both beat our estim ...

Flash | 23 Jul 2026 03:38:16 ET │ 10 pages Chugai Pharmaceutical (4519.T) Implications of results at Roche and Galderma CITI'S TAKE Roche and Galderma announced results at 14:00 PM Japan time. We discuss implications for Chugai. Roche's Japan sales grew 11% in CER terms, with Q1 up 14% and Q2 up 9%, for a solid performance. Sales of Hemlibra, Lunsumio, Elevidys, and Vabysmo were good as well. Sales to third parties were also strong, due likely in part to strong Nemluvio sales at Galderma (Q2: $266mn, Q1: $1 ...

July 23, 2026 07:22 AM GMT Chugai Pharmaceutical (4519) | Japan M Update Roche and Galderma 2Q26 Results: Slightly Positive for Chugai Key Takeaways On Jul 23, Roche (covered by Sarita Kapila) and Galderma (covered by Thibault Boutherin) reported 2Q26 results. Roche maintained its full-year guidance, while Galderma raised guidance. Others: Global Actemra sales declined 14% YoY in Apr-Jun, worsening from -4% in Jan-Mar. Enspryng has completed its US filing for TED and remains on track for a MOGAD filing in 2 ...